Cardinal Health raises FY2023 EPS outlook, provides FY2024 guide of $6.45-$6.70, $3.5B buyback

CARDINAL HEALTH INC

Narrows FY2023 non-GAAP EPS guidance to $5.65-$5.80 (mid-point 13% growth); preliminary FY2024 guidance $6.45-$6.70 (15% growth).
Long-term target: 12%-14% non-GAAP EPS CAGR over FY2024-2026; Pharmaceutical segment profit growth 4%-6%.
Board approves new $3.5B share repurchase authorization through 2027; plans at least $2B in buybacks over next three years.
Launches Navista Network for community oncology; retains and invests in Nuclear & Precision Health Solutions.
Medical Improvement Plan targets $650M+ segment profit by FY2026; $400M expected in FY2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.